Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Solstice Pharmaceuticals B V manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units.
MEJIAS, SAMANTHA LEE is the busiest examiner, holding 1 pending office action. With 2 distinct examiners each managing an action, the company's current prosecution workload is split evenly between the two identified art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEJIAS, SAMANTHA LEE | 1 | 46.7% | +40.0% |
| PATEL, SHEFALI DILIP | 1 | 58.1% | +27.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17638621 | Cartridge for Mixing a Liquid Intended for Intracorporeal Use | PATEL, SHEFALI DILIP | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259201 | Process for Controlled Manufacturing of Mono-Disperse Microbubbles | MEJIAS, SAMANTHA LEE | — |
| 17638621 | Cartridge for Mixing a Liquid Intended for Intracorporeal Use | PATEL, SHEFALI DILIP | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18259201 | Process for Controlled Manufacturing of Mono-Disperse Microbubbles | MEJIAS, SAMANTHA LEE | 1618 | §103 | Final Rejection | — | Pending | Jun 23, 2023 |
| 17638621 | Cartridge for Mixing a Liquid Intended for Intracorporeal Use | PATEL, SHEFALI DILIP | 3783 | §102§103§112 | Final Rejection | — | Pending | Feb 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSolstice Pharmaceuticals B V has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Samantha Lee Mejias has the most, with 1 of Solstice Pharmaceuticals B V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
